- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in...
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation...
PALO ALTO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or...
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and...
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or...
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a...
PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a...
- BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with...
- Submitted New Drug Application (NDA) to US Food and Drug Administration (FDA) for acoramidis for the...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.